.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Precision Medicine in Advanced Non-Small Cell Lung Cancer

EP. 1: Osimertinib As Frontline Therapy in EGFR-Positive NSCLC

July 26th 2018

EP. 2: Osimertinib in EGFR-Positive NSCLC With Brain Metastases

July 26th 2018

EP. 3: Sequencing With Osimertinib in EGFR-Positive NSCLC

July 26th 2018

EP. 4: Resistance Mechanisms in EGFR-Positive NSCLC

July 26th 2018

EP. 5: Managing Resistance to EGFR TKIs in NSCLC

July 26th 2018

EP. 6: Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

July 26th 2018

EP. 7: EGFR TKIs as Adjuvant Therapy in NSCLC

July 26th 2018

EP. 8: Emerging Therapies in EGFR-Positive NSCLC

July 26th 2018

EP. 9: Alectinib in ALK-Mutated NSCLC

July 26th 2018

EP. 10: Treating ALK-Mutated NSCLC With Disease Progression

July 26th 2018

EP. 11: Managing Resistance to ALK Inhibitors in NSCLC

July 26th 2018

EP. 12: Treatment Considerations in ALK/ROS-1 Rearranged NSCLC

July 26th 2018

EP. 13: Combination Therapy in BRAF-Mutant NSCLC

July 26th 2018

EP. 14: Treating Rare Actionable Mutations in NSCLC

July 26th 2018

EP. 15: Significance of Next-Generation Sequencing in NSCLC

July 26th 2018

EP. 16: Best Practices in Molecular Profiling in NSCLC

July 26th 2018

EP. 17: Rationale for Liquid Biopsies in NSCLC

July 26th 2018